KR920009412A - ICAM-1의 Mac-1 결합 부위 - Google Patents

ICAM-1의 Mac-1 결합 부위 Download PDF

Info

Publication number
KR920009412A
KR920009412A KR1019910021347A KR910021347A KR920009412A KR 920009412 A KR920009412 A KR 920009412A KR 1019910021347 A KR1019910021347 A KR 1019910021347A KR 910021347 A KR910021347 A KR 910021347A KR 920009412 A KR920009412 A KR 920009412A
Authority
KR
South Korea
Prior art keywords
icam
functional derivative
mac
response
lfa
Prior art date
Application number
KR1019910021347A
Other languages
English (en)
Inventor
에스. 다이아몬드 마이클
이. 스타운톤 도날드
에이. 스프링거 티모시
Original Assignee
원본미기재
센터 포 블러드 리서어치 래보라토리즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 센터 포 블러드 리서어치 래보라토리즈, 인코포레이티드 filed Critical 원본미기재
Publication of KR920009412A publication Critical patent/KR920009412A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ropes Or Cables (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Package Frames And Binding Bands (AREA)
  • Hall/Mr Elements (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

ICAM-1의 Mac-1 결합 부위
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 정제된 ICAM-1에 대한 LFA-1 및 Mac-1 COS 세포 변형체의 유착을 나타내는 그래프,
제2도는 정제된 Mac-1에 대한 ICAM-1+L세포 유착의 용량 반응곡선을 나타내는 그래프,
제3도는 정제된 Mac-1 및 LFA←1에 대한 ICAM-1+L세포의 결합력을 비교하는 그래프.

Claims (24)

  1. Mac-1에는 실질적으로 결합할 수 없지만 LFA-1에는 실질적으로 결합할 수 있는 ICAM-1 작용성 유도체.
  2. 제1항에 있어서, 가용성 ICAM-1 작용성 유도체인 ICAM-1 작용성 유도체.
  3. 제2항에 있어서, ICAM-1의 도메인 1,2,3,4 및 5를 포함하며 가용성인 ICAM-1 작용성 유도체.
  4. 제3항에 있어서, ICAM-1의 도메인 3에 돌연변이를 포함하는 ICAM-1 작용성 유도체.
  5. 제4항에 있어서, 돌연변이가 ICAM-1의 잔기 229-231 및 잔기 254-256의 그룹중에서 선택된 잔기내에서 일어난 ICAM-1 작용성 유도체.
  6. LFA-1에는 실질적으로 결합할 수 없지만 Mac-1에는 실질적으로 결합할 수 있는 ICAM-1 작용성 유도체.
  7. 제6항에 있어서, 가용성 ICAM-1 작용성 유도체인 ICAM-1 작용성 유도체.
  8. 제7항에 있어서, ICAM-1의 도메인 1,2,3,4 및 5를 포함하며 가용성인 ICAM-1 작용성 유도체.
  9. 제8항에 있어서, ICAM-1의 도메인 1에 돌연변이를 포함하는 ICAM-1 작용성 유도체.
  10. 제9항에 있어서, 돌연변이가 ICAM-1의 E34, Q58ED 및 Q73의 그룹중에서 선택된 잔기내에서 일어난 ICAM-1 작용성 유도체.
  11. 제8항에 있어서, ICAM-1의 도메인 2에 돌연변이를 포함하는 ICAM-1 작용성 유도체.
  12. 제7항에 있어서, ICAM-1의 도메인 3과 4를 포함하며 가용성인 ICAM-1 작용성 유도체.
  13. Mac-1과 LFA-1에는 실질적으로 결합할 수 없지만 인간 리노바이러스를 실질적으로 결합시킬 수 있는 ICAM-1 작용성 유도체.
  14. Mac-1에 대한 결합 능력을 증대시킬 수 있는, 글리코실화 부위가 결여된 ICAM-1 작용성 유도체.
  15. 제14항에 있어서, 글리코실화 부위가 ICAM-1의 N269, N240 및 N358로 이루어진 그룹중에서 선택된 ICAM-1 작용성 유도체.
  16. 비-특이적 방어계의 반응에 의해 유발된 염증은 치료할 수 있지만 특이적 방어계의 반응에 의해 유발된 염증은 실질적으로 억제할 수 없음을 특징으로 하는 소염제.
  17. 제16항에 있어서, LFA-1에는 실질적으로 결합할 수 없지만 Mac-1에는 실질적으로 결합할 수 있는 ICAM-1 작용성 유도체인 소염제.
  18. 제17항에 있어서, 가용성 ICAM-1 작용성 유도체인 소염제.
  19. 특이적 방어계의 반응에 의해 유발된 염증은 치료할 수 있지만 비-특이적 방어계의 반응에 의해 유발된 염증은 실질적으로 억제할 수 없음을 특징으로 하는 소염제.
  20. 제19항에 있어서, Mac-1에는 실질적으로 결합할 수 없지만 LFA-1에는 실질적으로 결합할 수 있는 ICAM-1 작용성 유도체인 소염제.
  21. 제20항에 있어서, 가용성 ICAM-1 작용성 유도체인 소염제.
  22. 비-특이적 방어계의 반응에 의해 유발된 염증은 실질적으로 억제하지 않으면서 특이적 방어계의 반응에 의해 유발된 염증을 치료하기 위한 약제학적 제제를 제조하는데 있어서의 제1내지 5항중 어느 하나에 따른 화합물, 또는 LFA-1 또는 LFA-1 작용성 유도체, 안티-LFA-1 항체 또는 안티-ICAM-1 항체의 용도.
  23. 특이적 방어계의 반응에 의해 유발된 염증은 실질적으로 억제하지 않으면서 비-특이적 방어계의 반응에 의해 유발된 염증을 치료하기 위한 약제학적 제제제를 제조하는데 있어서의 제6내지 12, 14 및 15항중 어느 하나에 따른 화합물, 또는 Mac-1, Mac-1 작용성 유도체, 안티-Mac-1 항체 또는 안티-ICAM-1 항체의 용도.
  24. 특이적 또는 비-특이적 방어계의 반응에 의해 유발된 염증은 실질적으로 억제하지 않으면서 리노바이러스 감염을 치료 또는 예방하기 위한 약제학적 제제를 제조하는데 있어서의 제13항에 따른 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910021347A 1990-11-28 1991-11-26 ICAM-1의 Mac-1 결합 부위 KR920009412A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/618,286 US5288854A (en) 1990-11-28 1990-11-28 Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US618,286 1990-11-28

Publications (1)

Publication Number Publication Date
KR920009412A true KR920009412A (ko) 1992-06-25

Family

ID=24477094

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910021347A KR920009412A (ko) 1990-11-28 1991-11-26 ICAM-1의 Mac-1 결합 부위

Country Status (8)

Country Link
US (1) US5288854A (ko)
EP (1) EP0488061B1 (ko)
KR (1) KR920009412A (ko)
AT (1) ATE172988T1 (ko)
DE (1) DE69130445T2 (ko)
DK (1) DK0488061T3 (ko)
ES (1) ES2122964T3 (ko)
NZ (2) NZ260473A (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6797270B1 (en) 1989-03-16 2004-09-28 Center For Blood Research, Inc. Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
DE69131564T2 (de) * 1990-07-20 2000-01-13 Bayer Ag Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
CA2144738A1 (en) * 1992-10-09 1994-04-28 Michael Diamond A subpopulation of mac-1 (cd11b/cd18) molecules which mediate neutrophil adhesion to icam-1 and fibrinogen
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
ATE298248T1 (de) * 1998-04-15 2005-07-15 Brigham & Womens Hospital T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
US6867203B2 (en) 1998-12-29 2005-03-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
DE60140457D1 (de) * 2000-09-01 2009-12-24 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
HUP0402305A2 (hu) * 2000-11-28 2005-02-28 Genentech, Inc. LFA-1-antagonista vegyületek, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
PL1682537T3 (pl) * 2003-11-05 2012-09-28 Sarcode Bioscience Inc Modulatory adhezji komórkowej
AU2005277547B2 (en) 2004-08-16 2011-08-25 Immune Disease Institute, Inc. Method of delivering RNA interference and uses thereof
US20060233675A1 (en) * 2005-04-13 2006-10-19 Stein Israel M Glass test tube having protective outer shield
CA2609053C (en) * 2005-05-17 2017-04-25 Sarcode Corporation Compositions and methods for treatment of eye disorders
WO2007127272A2 (en) * 2006-04-24 2007-11-08 The Cbr Institute For Biomedical Research Method of producing immunoliposomes and compositions thereof
US20100008937A1 (en) * 2006-04-25 2010-01-14 Immune Disease Institute, Inc. Targeted delivery to leukocytes using non-protein carriers
EP3797775A1 (en) 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
JP2011518155A (ja) * 2008-04-15 2011-06-23 サーコード コーポレイション 免疫関連障害の局所治療に使用するためのエアゾール化ｌｆａ−１アンタゴニスト
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN104797574B (zh) 2012-07-25 2019-11-22 原生质生物科学股份有限公司 Lfa-1抑制剂及其多晶型物
EP3897851A2 (en) 2018-12-17 2021-10-27 Revitope Limited Twin immune cell engager

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0314863B1 (en) * 1987-11-02 1994-12-07 Baylor College Of Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation
ES2141076T3 (es) * 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
ES2077572T3 (es) * 1988-09-28 1995-12-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular, y sus ligandos de fijacion.

Also Published As

Publication number Publication date
NZ260473A (en) 1997-06-24
DK0488061T3 (da) 1999-07-19
US5288854A (en) 1994-02-22
EP0488061A2 (en) 1992-06-03
NZ240747A (en) 1996-05-28
EP0488061A3 (en) 1992-08-26
EP0488061B1 (en) 1998-11-04
DE69130445T2 (de) 1999-07-08
ES2122964T3 (es) 1999-01-01
DE69130445D1 (de) 1998-12-10
ATE172988T1 (de) 1998-11-15

Similar Documents

Publication Publication Date Title
KR920009412A (ko) ICAM-1의 Mac-1 결합 부위
KR930009607A (ko) 증식성 질환의 치료를 위한 다이피리다몰
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
KR930016102A (ko) 과증식 혈관 질환 치료용 조성물
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
IS4073A (is) Nýtt fjölvirknislyf gegn aukningu mótstöðu
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
DE69328550T2 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
TR199901417T2 (xx) Analjezik etkisi olan yeni bile�imler.
DE69535805D1 (de) Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz
ATE221881T1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
BR9813256A (pt) Composto, composição farmacêutica, e, processos para tratar de um paciente com uma doença neurodegenerativa, para prevenir o inìcio de uma doença neurodegenerativa em um paciente, para tratar de um paciente com uma doença autoimune, para prevenir o inìcio de uma doença autoimune em um paciente, para tratar de um paciente com uma doença inflamatória e para prevenir o inìcio de uma doença inflamatória em um paciente
DE69320646T2 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'-halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
AR029190A1 (es) Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
KR940018087A (ko) 진통제 및 소염제로서의 6-클로로-5-플루오로-3-(2-테노일)-2-옥신돌-ⅰ-카복스아미드
TR199800717T2 (xx) Amyotrofik lateral skleroz tedavisine y�nelik ila� haz�rlamak i�in
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
KR950031085A (ko) 표피증식 질환 치료용 의약 조성물
DE69629436D1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
FR2559668B1 (fr) Compositions pharmaceutiques pour le traitement du diabete et de maladies et defauts de fonctionnement du foie
Bolla et al. Prevention of recurrences in frequently relapsing herpes labialis with thymopentin a randomized double-blind placebo-controlled multicenter study
FR2594332B1 (fr) Derives d'acides amino-benzoiques, d'acides hydroxy-benzoiques, d'acides cinnamiques, d'acide urocanique et de benzimidazole presentant ou non un groupement d'acide amine absorbant les uvb et/ou les uva et permettant d'eviter les photodermatoses, chez l'homme, consecutives a l'administration de medicaments, a l'emploi de cosmetiques parfumes ou de parfums
DE69814691T2 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten
ATE71645T1 (de) Durch polyaddition haertbare, jod enthaltende siloxan-elastomer-zusammensetzung.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee